| __timestamp | Amicus Therapeutics, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 581800000 |
| Thursday, January 1, 2015 | 76943000 | 671900000 |
| Friday, January 1, 2016 | 104793000 | 876700000 |
| Sunday, January 1, 2017 | 149310000 | 857900000 |
| Monday, January 1, 2018 | 270902000 | 822200000 |
| Tuesday, January 1, 2019 | 286378000 | 778200000 |
| Wednesday, January 1, 2020 | 308443000 | 512600000 |
| Friday, January 1, 2021 | 272049000 | 681000000 |
| Saturday, January 1, 2022 | 276677000 | 662200000 |
| Sunday, January 1, 2023 | 152381000 | 910700000 |
Unleashing the power of data
In the ever-evolving landscape of pharmaceuticals, innovation is the lifeblood of progress. Over the past decade, Viatris Inc. and Amicus Therapeutics, Inc. have demonstrated distinct approaches to research and development (R&D) investments. From 2014 to 2023, Viatris consistently allocated a significant portion of its resources to R&D, peaking in 2023 with a 56% increase from its 2014 spending. In contrast, Amicus Therapeutics showed a more fluctuating pattern, with a notable peak in 2020, where R&D spending was nearly six times that of 2014. However, by 2023, Amicus's investment had decreased by 50% from its 2020 high. This data underscores the strategic priorities of each company, with Viatris maintaining a steady commitment to innovation, while Amicus navigates a more variable path. As the pharmaceutical industry continues to advance, these investment strategies will play a crucial role in shaping future breakthroughs.
Research and Development: Comparing Key Metrics for Eli Lilly and Company and Amicus Therapeutics, Inc.
Comparing Innovation Spending: Incyte Corporation and Viatris Inc.
Research and Development Investment: Viatris Inc. vs Corcept Therapeutics Incorporated
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and Supernus Pharmaceuticals, Inc.
Viatris Inc. or Amphastar Pharmaceuticals, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Amicus Therapeutics, Inc.
R&D Insights: How Exelixis, Inc. and Amicus Therapeutics, Inc. Allocate Funds
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Amicus Therapeutics, Inc.
Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
R&D Spending Showdown: Perrigo Company plc vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Geron Corporation
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Galapagos NV